TIGIT Antibodies

T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a protein associated with the immune system. It is primarily expressed on the surface of various immune cells, including T cells and natural killer (NK) cells. It interacts with its ligands, CD155 (PVR) and CD112 (PVRL2), on antigen-presenting cells, leading to inhibitory signals that contribute to a complex network of immune checkpoints that balance the activation and inhibition of immune cells.

TIGIT has been studied in the context of various diseases, including cancer and autoimmune disorders. This protein can contribute to immune evasion in cancer by inhibiting the activity of cytotoxic T cells and NK cells. In autoimmune conditions, there may be dysregulation of its signaling, affecting the balance of immune responses.

Antibodies against TIGIT are used in research to study its expression levels, distribution, and interactions in different tissues and cells. They are valuable tools for understanding its role in immune regulation and its potential as a target for therapeutic intervention. Notably, antibodies targeting TIGIT, either alone or in combination with other immune checkpoint inhibitors, are being investigated in clinical trials. In this sense, diagnostic applications may involve assessing its expression in tumors to predict responses to immunotherapy.

Synonyms

T-cell immunoreceptor with Ig and ITIM domains, VSIG9|VSTM3|WUCAM

Research Areas

Apoptosis, Autophagy, Breast Cancer, Cancer, Cardiovascular, Cell Biology, Cellular Markers and Tags, Developmental Biology, Endocrine, Epigenetics, Gastrointestinal Tract, Hypoxia, Immuno Oncology, Immunology, Kidney, Lymphatic, Metabolism, Microbiology, Muscle, Neuroscience, Pancreatic Cancer, Prostate Cancer, Skin, Stem Cell, AKT Signaling, Angiogenesis, Articular Cartilage Extracellular Matrix, B Cell Markers, Basal Cell Marker, BBB VCAM-1 Signaling, Bladder Cancer, Cardiac Stem Cells, Colon Cancer, Colorectal Cancer, Complement System, CTLA-4 blockade immunotherapy, Cytokine Signaling, Defective Intrinsic Apoptosis, Dendritic Cell Marker, Digestion, Endothelial Cell Marker, Hematopoietic Stem Cells, Immune checkpoint, Infectious Disease, Lipid Metabolism, Lung Cancer, MAPK Signaling, Mast Cell Marker, Melanoma, Mesenchymal Stem Cell Differentiation, Mitochondria Marker, Neural Stem Cells, Neuroinflammation, Nuclear Marker, Oncology, Ovarian Cancer, PD-1 blockade immunotherapy, Signal Transduction, Stem Cell Differentiation, Transcription Factors